Skip to main content
Signal8
Launch Terminal

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

NASDAQ:ACRSHealthcare
-0.50%$3.97
AH$4.03+1.51%vs close
Mkt Cap$615.29M
Float121.51M
O/S154.98M
Vol
$ Vol
RVOL
Inst Own77.0%
SI12.4%
Earnings
Dilution
Aclaris Therapeutics, Inc. logoNASDAQ:ACRS$3.97-0.50%
Upcoming Catalysts
  • ATI-052READOUT
    Cash runway at this date: 2yr
    Oct 27, 20266d ago8-K
Phase Distribution
33 lead-sponsored trials·1 active·28 completed
Phase 1/21
Phase 224
Phase 36
Phase 42
(3 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

    Oxymetazoline HCL 1.0% Cream

    Rosacea

    Enrollment
    46
    Start
    Dec 2017
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT03380390
  • Phase 4
    Completed

    An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

    A-101 Topical Solution

    Seborrheic Keratosis

    Enrollment
    41
    Start
    Mar 2018
    Primary Completion
    Nov 2018
    Completion
    Nov 2018
    NCT03487588
  • Phase 3
    Completed

    A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

    A-101 Solution

    Seborrheic Keratosis

    Enrollment
    450
    Start
    Jan 2016
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02667236
  • Phase 3
    Completed

    A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

    A-101 Solution

    Seborrheic Keratosis

    Enrollment
    487
    Start
    Jan 2016
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02667275
  • Phase 3
    Completed

    An Open-Label Safety Study of A-101 Solution

    A-101 Solution

    Seborrheic Keratosis

    Enrollment
    147
    Start
    Jan 2016
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02667288
  • Phase 3
    Completed

    Study of A-101 Topical Solution for the Treatment of Common Warts

    A-101

    Common Wart

    Enrollment
    503
    Start
    Sep 2018
    Primary Completion
    Jun 2019
    Completion
    Sep 2019
    NCT03687372
  • Phase 3
    Completed

    A Study of A-101 Topical Solution for the Treatment of Common Warts

    Active

    Common Wart

    Enrollment
    502
    Start
    Sep 2018
    Primary Completion
    Apr 2019
    Completion
    Jul 2019
    NCT03691831
  • Phase 3
    Completed

    Safety Study of A-101 Topical Solution for the Treatment of Common Warts

    A-101

    Common Wart

    Enrollment
    426
    Start
    Feb 2019
    Primary Completion
    Nov 2019
    Completion
    Dec 2019
    NCT03812510
  • Phase 2
    Completed

    Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

    A-101 Vehicle, A-101 (40) Topical Solution

    Seborrheic Keratosis

    Enrollment
    172
    Start
    Jun 2014
    Primary Completion
    Dec 2014
    Completion
    Dec 2014
    NCT02160626
  • Phase 2
    Completed

    Study of A-101 for the Treatment of Seborrheic Keratosis

    A-101

    Seborrheic Keratosis

    Enrollment
    119
    Start
    Oct 2014
    Primary Completion
    Mar 2015
    Completion
    Mar 2015
    NCT02260180
  • Phase 2
    Completed

    A Study of A-101 Solution in Subjects With Common Warts.

    A-101 Solution 40, A-101 Solution 45

    Common Warts

    Enrollment
    98
    Start
    Dec 2015
    Primary Completion
    Sep 2016
    Completion
    Sep 2016
    NCT02669862
  • Phase 2
    Completed

    A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

    A-101

    Seborrheic Keratosis

    Enrollment
    253
    Start
    May 2017
    Primary Completion
    Feb 2018
    Completion
    Apr 2018
    NCT03148691
  • Phase 2
    Completed

    A Phase2 of A-101 Topical Solution in Subjects With Common Warts

    A-101 Topical Solution, A-101 Vehicle Solution

    Common Wart

    Enrollment
    157
    Start
    Aug 2017
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT03210337
  • Phase 2
    Completed

    A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

    A-101 Topical Solution 40%

    Dermatosis Papulosa Nigra

    Enrollment
    39
    Start
    Jun 2017
    Primary Completion
    Jan 2019
    Completion
    Jan 2019
    NCT03224598
  • Phase 2
    Completed

    A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

    A-101 Topical Solution, A-101 Vehicle Solution

    Common Wart

    Enrollment
    159
    Start
    Jul 2017
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT03278028
  • Phase 2
    Completed

    Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

    Vehicle, ATI-50002

    Alopecia Universalis (AU), Alopecia Totalis (AT)

    Enrollment
    11
    Start
    Dec 2017
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03315689
  • Phase 2
    Terminated

    A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

    ATI-50002 high dose, ATI-50002 low dose

    Alopecia Areata

    Enrollment
    129
    Start
    Nov 2017
    Primary Completion
    Apr 2019
    Completion
    Sep 2019
    NCT03354637
  • Phase 2
    Completed

    A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

    ATI-50002 topical solution

    Vitiligo

    Enrollment
    34
    Start
    Mar 2018
    Primary Completion
    Oct 2019
    Completion
    Oct 2019
    NCT03468855
  • Phase 2
    Completed

    A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

    ATI-50002

    Androgenetic Alopecia

    Enrollment
    31
    Start
    Mar 2018
    Primary Completion
    Oct 2019
    Completion
    Oct 2019
    NCT03495817
  • Phase 2
    Completed

    Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

    ATI-50002

    Alopecia Areata, Alopecia Totalis +1

    Enrollment
    1
    Start
    Apr 2018
    Primary Completion
    Nov 2018
    Completion
    Nov 2018
    NCT03551821
  • Phase 2
    Completed

    A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

    ATI-502

    Atopic Dermatitis

    Enrollment
    22
    Start
    Jul 2018
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT03585296
  • Phase 2
    Completed

    ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

    ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose)

    Alopecia

    Enrollment
    87
    Start
    Jun 2018
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03594227
  • Phase 2
    Terminated

    ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

    ATI 502 0.46% Topical Solution

    Alopecia Areata, Alopecia Universalis +1

    Enrollment
    56
    Start
    Jan 2019
    Primary Completion
    Sep 2019
    Completion
    Sep 2019
    NCT03759340
  • Phase 2
    Completed

    Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

    ATI-450, Placebo oral tablet

    Rheumatoid Arthritis

    Enrollment
    25
    Start
    Mar 2020
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04247815
  • Phase 2
    Terminated

    Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

    ATI-450

    Cryopyrin-Associated Periodic Syndrome

    Enrollment
    1
    Start
    Oct 2020
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04524858

1-25 of 33

Search ClinicalTrials.gov for “Aclaris Therapeutics”